Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › upadacitinib

upadacitinib

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of upadacitinib

30 trials tracked of upadacitinib: 21 in phase 3 or 4 and 18 with published results. The most-cited published study has 509 citations.

30Trials tracked
21Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 1 Phase 3 20 Phase 2 9
  1. Phase 3 A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis Completed · 509 cited
  2. Phase 3 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis Completed · 105 cited
  3. Phase 3 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs Completed · 67 cited
  4. Phase 3 A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) Completed · 62 cited
  5. Phase 3 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy Completed · 60 cited
  6. Phase 3 A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs Completed · 56 cited
Show 24 more trials
  1. Phase 3 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs Completed · 56 cited
  2. Phase 3 A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) Completed · 55 cited
  3. Phase 3 A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Completed · 55 cited
  4. Phase 3 A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone Completed · 55 cited
  5. Phase 3 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) Completed · 31 cited
  6. Phase 3 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug Completed · 31 cited
  7. Phase 3 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis Completed · 29 cited
  8. Phase 3 Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) Completed · 29 cited
  9. Phase 3 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 29 cited
  10. Phase 3 A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) Completed · 28 cited
  11. Phase 3 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies Completed · 15 cited
  12. Phase 3 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Completed · 3 cited
  13. Phase 4 A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis Completed
  14. Phase 3 A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) Completed
  15. Phase 3 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis Completed
  16. Phase 2 A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis Completed
  17. Phase 2 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Completed
  18. Phase 2 An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis Completed
  19. Phase 2 A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed
  20. Phase 2 A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis Completed
  21. Phase 2 A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms Completed
  22. Phase 2 A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis Completed
  23. Phase 2 A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone Completed
  24. Phase 2 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
Dermatology Meta-analysis
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs Common arthritis and skin drugs linked to cholesterol changes, analysis finds
A systematic review and meta-analysis of 13 phase 2 and 3 RCTs involving 5,658 patients found treatment with oral JAK inhibitors (baricitini…
Common arthritis and skin drugs can raise both 'good' and 'bad' cholesterol levels, a review of nearly 4,000 patients shows.
Apr 4, 2026
Network meta-analysis ranks upadacitinib highest for efficacy in moderate-to-severe atopic dermatitis
Dermatology Meta-analysis
Network meta-analysis ranks upadacitinib highest for efficacy in moderate-to-severe atopic dermatitis Study compares eczema medications, finds upadacitinib 30 mg ranked highest for effectiveness
A network meta-analysis of 16,334 adults with moderate-to-severe atopic dermatitis compared approved systemic targeted therapies.
Upadacitinib 30 mg ranked highest for clearing skin and reducing itch among approved eczema medications in a new analysis of over 16,000 pat…
Apr 1, 2026